PRTK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRTK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), the Forward Annual Dividend Yield of Paratek Pharmaceuticals is 0.00%.
As of today (2024-04-27), the Trailing Annual Dividend Yield of Paratek Pharmaceuticals is 0.00%.
Paratek Pharmaceuticals's Dividends per Share for the three months ended in Jun. 2023 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
For the Biotechnology subindustry, Paratek Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Paratek Pharmaceuticals's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Paratek Pharmaceuticals (NAS:PRTK) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Minnie Baylor-henry | director | C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803 |
Kristine Peterson | director | AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355 |
Timothy R Franson | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Jeffrey Stein | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Thomas John Dietz | director | C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804 |
Evan Loh | director, officer: CEO | 75 KNEELAND STREET, BOSTON MA 02111 |
William M. Haskel | officer: CLO, General Counsel & Sec. | ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073 |
Adam Woodrow | officer: President & Chief Commercial | C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111 |
Randall B. Brenner | officer: Chief Development & Regulatory | C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116 |
Robert S Radie | director | 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355 |
Rolf K Hoffmann | director | LORBEERWEG 7, WEGGIS V8 CH-6353 |
Michael Bigham | director, officer: Exec. Chairman of the Board | 890 WINTER STREET, WALTHAM MA 02451 |
James D Dondero | 10 percent owner | 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201 |
Douglas W. Pagan | officer: Chief Financial Officer | 75 KNEELAND STREET, BOSTON MA 02111 |
Omega Fund Iv, L.p. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
From GuruFocus
By Marketwired • 06-27-2023
By Marketwired • 06-27-2023
By Marketwired • 09-18-2023
By PRNewswire • 06-27-2023
By Marketwired • 07-17-2023
By Business Wire Business Wire • 06-11-2023
By Marketwired • 07-18-2023
By PRNewswire • 06-29-2023
By Marketwired • 08-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.